News

BioAgora Open Call: Science - Policy - Society Interface (SPSI) capacity development initiatives

Published on | 1 year ago

Programmes
Agro-Food, Environment

BioAgora is launching a new funding call for capacity development initiatives aimed at capacity building across the science-policy-society interface. BioAgora is a collaborative European project funded by the Horizon Europe programme.

This call invites proposals for a wide range of capacity development activities which enhance skills and capacities of scientists, policymakers and other actors to collaborate at the science-policy-society interface.

Who can apply?

This funding call is open to legal entities or consortia of legal entities eligible for Horizon Europe funding. Projects should involve participants from across Europe and prioritize transdisciplinary collaboration, incorporating social and environmental disciplines.

Funding details

Total Available Funding: €350,000

Maximum Grant per Project: €175,000

Number of Projects: 2-5 funded projects, depending on project size

Project Start Date: May 2025 (earliest)

Project End Date: December 2026

Submission Deadline: 27 January 2025 22:00 (CET)

Call announcement is on the EC portal: Calls for proposals | EU Funding & Tenders Portal

For more information on this call and on how to submit a proposal: First BioAgora Cascade Funding Call: Capacity Development Initiatives at the Science-Policy-Society Interface (SPSI)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1958 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.